News | May 26, 2025
Biocon Biologics receives MHRA, UK approval for biosimilar YESINTEK
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Subscribe To Our Newsletter & Stay Updated
